What the trial was testing
The ZUMA-7 enrolled 359 patients with lymphoma. The study was sponsored by Kite, A Gilead Company and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
65% of patients saw their lymphoma disappear completely after the gene therapy.
The New England journal of medicine · 2022 · NCT03391466
These findings — that lymphoma disappeared completely in two-thirds of gene therapy patients — were published in the The New England journal of medicine and represent the headline result of the study.
Researchers tracked outcomes across 359 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with lymphoma, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This gene therapy is FDA-approved for certain lymphoma patients whose cancer came back quickly. It works by reprogramming your own immune cells to attack the cancer. Ask your doctor if this treatment is right for you — it's now a standard option for people whose lymphoma returns within a year of first treatment.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open lymphoma trials
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
This study assesses the quality of life in patients with cutaneous lymphoma diagnosis as it relates to their personal, clinical, and therapeutic information using the Skindex29 questionnaire and also assesses patients' understanding of their diagnosis and need for resources related to their care. Cutaneous lymphomas are a rare type of blood cancers (non-Hodgkin lymphoma) that present in the skin. The information gained from this study, may help researchers improve quality of life in cutaneous lymphoma patients.
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
This is a double-center, single-arm, phase 2 study to evaluate the efficacy and safety of R-CDOP regimen combined with intrathecal methotrexate in chemo-naive diffuse large B-cell lymphoma patients with high-risk of CNS relapse.